HK1076389A1 - Use of sulfated glycosaminoglycans for the manufacture of a pharmaceutical preparation for the prevention and treatment of slow progress of term labor - Google Patents

Use of sulfated glycosaminoglycans for the manufacture of a pharmaceutical preparation for the prevention and treatment of slow progress of term labor

Info

Publication number
HK1076389A1
HK1076389A1 HK05108458A HK05108458A HK1076389A1 HK 1076389 A1 HK1076389 A1 HK 1076389A1 HK 05108458 A HK05108458 A HK 05108458A HK 05108458 A HK05108458 A HK 05108458A HK 1076389 A1 HK1076389 A1 HK 1076389A1
Authority
HK
Hong Kong
Prior art keywords
pregnant woman
labor
treatment
myometrium
cervix
Prior art date
Application number
HK05108458A
Other languages
English (en)
Inventor
Gunvor Ekman-Ordeberg
Anders Malmostrom
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dilafor Ab filed Critical Dilafor Ab
Publication of HK1076389A1 publication Critical patent/HK1076389A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK05108458A 2002-01-02 2005-09-26 Use of sulfated glycosaminoglycans for the manufacture of a pharmaceutical preparation for the prevention and treatment of slow progress of term labor HK1076389A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200005A SE521676C2 (sv) 2002-01-02 2002-01-02 Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
PCT/SE2003/000004 WO2003055499A1 (en) 2002-01-02 2003-01-02 Use of sulfated glycosaminoglycans for establishing effective labor in women

Publications (1)

Publication Number Publication Date
HK1076389A1 true HK1076389A1 (en) 2006-01-20

Family

ID=20286575

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05108458A HK1076389A1 (en) 2002-01-02 2005-09-26 Use of sulfated glycosaminoglycans for the manufacture of a pharmaceutical preparation for the prevention and treatment of slow progress of term labor

Country Status (22)

Country Link
US (3) US7407945B2 (de)
EP (1) EP1461049B1 (de)
JP (1) JP4434741B2 (de)
KR (1) KR100958691B1 (de)
CN (1) CN100341518C (de)
AT (1) ATE395067T1 (de)
AU (1) AU2003201787B2 (de)
CA (1) CA2472093C (de)
CY (1) CY1108260T1 (de)
DE (1) DE60320931D1 (de)
DK (1) DK1461049T3 (de)
ES (1) ES2306852T3 (de)
HK (1) HK1076389A1 (de)
IL (2) IL162664A0 (de)
NO (1) NO332702B1 (de)
NZ (1) NZ533856A (de)
PL (1) PL206458B1 (de)
PT (1) PT1461049E (de)
SE (1) SE521676C2 (de)
SI (1) SI1461049T1 (de)
WO (1) WO2003055499A1 (de)
ZA (1) ZA200405015B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN104144950B (zh) * 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
US20150057226A1 (en) * 2012-03-26 2015-02-26 Dilafor Ab Method for treatment of labor arrest
CN104203256B (zh) * 2012-03-26 2017-11-24 迪乐方有限责任公司 用于引产的包含硫酸化的葡糖胺聚糖的联合治疗
UA117912C2 (uk) * 2012-05-08 2018-10-25 Ділафор Аб Застосування гепарину або гепарансульфату для лікування післяпологової кровотечі (ппк)
KR20150039201A (ko) 2012-08-03 2015-04-09 엘에프비 유에스에이, 인크. 체외 막 산소공급에서의 안티트롬빈의 용도
US20230144378A1 (en) 2020-02-17 2023-05-11 Dilafor Ab Tafoxiparin for the treatment of preeclampsia
TW202406559A (zh) 2022-05-03 2024-02-16 瑞典商迪拉佛公司 塔夫西肝素(tafoxiparin)之新穎醫藥用途
EP4272749A1 (de) 2022-05-03 2023-11-08 Dilafor AB Neue medizinische verwendung von tafoxiparin

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0209924A1 (de) * 1985-07-12 1987-01-28 Akzo N.V. Antithrombotikum auf Basis von Glykosaminoglykan, Verfahren zu dessen Herstellung und pharmazeutische Zusammensetzung
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) * 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
SE8702254D0 (sv) 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US6020322A (en) * 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
ES2276404T3 (es) * 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
NZ330603A (en) * 1996-10-15 2000-01-28 Toray Industries Hyaluronic acid derivatives used as cervical ripening agents
JP4412756B2 (ja) 1998-02-26 2010-02-10 生化学工業株式会社 新規多糖誘導体、その製造法及びそれを有効成分とする医薬組成物
US6194391B1 (en) * 1998-06-24 2001-02-27 Emory University 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
JP2000309544A (ja) * 1999-02-25 2000-11-07 Seikagaku Kogyo Co Ltd 早産または流産防止剤および子宮頚管熟化抑制剤ならびにヒアルロニダーゼの阻害剤
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet

Also Published As

Publication number Publication date
SE521676C2 (sv) 2003-11-25
DK1461049T3 (da) 2008-09-15
IL162664A (en) 2009-06-15
WO2003055499A1 (en) 2003-07-10
CA2472093C (en) 2011-02-22
PL206458B1 (pl) 2010-08-31
CN1612741A (zh) 2005-05-04
AU2003201787A1 (en) 2003-07-15
PT1461049E (pt) 2008-08-22
US8524688B2 (en) 2013-09-03
ES2306852T3 (es) 2008-11-16
KR100958691B1 (ko) 2010-05-18
SI1461049T1 (sl) 2008-12-31
CA2472093A1 (en) 2003-07-10
US8207145B2 (en) 2012-06-26
US20120225843A1 (en) 2012-09-06
NO332702B1 (no) 2012-12-10
US20050075314A1 (en) 2005-04-07
ATE395067T1 (de) 2008-05-15
EP1461049A1 (de) 2004-09-29
KR20040075917A (ko) 2004-08-30
SE0200005D0 (sv) 2002-01-02
JP4434741B2 (ja) 2010-03-17
AU2003201787B2 (en) 2008-02-28
US20080269165A1 (en) 2008-10-30
JP2005513148A (ja) 2005-05-12
PL370428A1 (en) 2005-05-30
NZ533856A (en) 2004-12-24
DE60320931D1 (de) 2008-06-26
EP1461049B1 (de) 2008-05-14
NO20043190L (no) 2004-07-26
US7407945B2 (en) 2008-08-05
CY1108260T1 (el) 2014-02-12
CN100341518C (zh) 2007-10-10
IL162664A0 (en) 2005-11-20
SE0200005L (sv) 2003-07-03
ZA200405015B (en) 2005-08-31

Similar Documents

Publication Publication Date Title
HK1076389A1 (en) Use of sulfated glycosaminoglycans for the manufacture of a pharmaceutical preparation for the prevention and treatment of slow progress of term labor
Shaughnessy et al. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria
BRPI0511603A (pt) método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados
Middeldorp Heparin: from animal organ extract to designer drug
EP0066908B1 (de) Antithrombotikum auf Basis von Polysacchariden, Verfahren zur dessen Herstellung und medizinale Zusammensetzungen
TWI383796B (zh) Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer
Turpie et al. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies
EP2830634A1 (de) Verfahren zur behandlung von wehenhemmung
Mukherjee et al. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin
CZ20014665A3 (cs) Prostředek s obsahem heparinu se střední molekulovou hmotností
Van Ryn-McKenna et al. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli
Thodiyil et al. Thromboprophylaxis in the cancer patient
CA2519797A1 (en) Low molecular weight hyaluronic acid for the treatment of nerve damage
KR950704362A (ko) 항혈전제
JP3218039B2 (ja) 硫酸化多糖類，それらの調製法，医薬組成物および使用
Harenberg et al. Pharmacology and special clinical applications of low‐molecular‐weight heparins
Cohen et al. The essence trial: efficacy and safety of subcutaneous enoxaparin in unstable angina and non-Q-wave MI: a double-blind, randomized, parallel-group, multicenter study comparing enoxaparin and intravenous unfractionated heparin: methods and design
Chiapuzzo et al. The use of low molecular weight heparins for post-surgical deep vein thrombosis prevention in orthopaedic patients
Vinazzer Advantages of low molecular weight heparin over standard heparin: facts and fiction
RU2014149230A (ru) Лечение послеродового кровотечения (прк)
JP2005505537A (ja) 低分子量ヘパリンと低分子量デルマタン硫酸とを含む抗血栓組成物
Agnelli Pharmacological activities of heparin chains: should our past knowledge be revised?
Steiner et al. A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with acenocoumarol) in patients undergoing gynaecological surgery
EP1537871A1 (de) Enoxaparin in der Tumorenbehandlung
Ahmed et al. The Use of Hyaluronic Acid in Reducing Postoperative Complications in Minor Oral Surgery: A Review

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190102